Company profile: Roxro Pharma
1.1 - Company Overview
Company description
- Provider of intranasal pain-treatment drugs, offering ROX-888 for dental and postoperative pain and ROX-828, a non-opioid, non-triptan intranasal therapy for migraine.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Roxro Pharma
Eledon Pharmaceuticals
HQ: United States
Website
- Description: Provider of biotechnology therapies and clinical programs for organ and cellular transplantation, featuring tegoprubart, a therapeutic antibody to regulate immune response and prevent rejection. Offers the Phase 2 BESTOW kidney transplant trial, support resources for transplant patients, and R&D in ALS, xenotransplantation, and islet cell transplantation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eledon Pharmaceuticals company profile →
Keystone Heart
HQ: Israel
Website
- Description: Provider of embolic cerebral protection medical devices for cardiovascular and structural heart procedures, developing and manufacturing devices that protect the brain from emboli and reduce the risk of brain infarcts during TAVR, AF ablation, and other procedures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Keystone Heart company profile →
Drug Abuse Sciences
HQ: United States
Website
- Description: Provider of therapies for alcohol and drug addictions, offering Naltrexone Depot, a sustained-release formulation of naltrexone for alcohol and opiate addictions; DAS-431 for cocaine addiction; and Buprenorphine Depot, a sustained-release formulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Drug Abuse Sciences company profile →
4P-Pharma
HQ: France
Website
- Description: Provider of clinical-stage regenerating active drugs and therapies for serious diseases, including 4P004, a GLP-1 analog for osteoarthritis; 4P022, an AI platform-based treatment for systemic sclerosis; 4P025 for primary sclerosing cholangitis; 4P021, a CXCR4 antagonist for acute respiratory distress syndrome and pulmonary complications; and 4P020, a beta-3 adrenergic receptor agonist for Stargardt disease and dry age-related macular degeneration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4P-Pharma company profile →
eNeura
HQ: United States
Website
- Description: Provider of non-invasive single-pulse transcranial magnetic stimulation (sTMS) devices and digital tools for migraine treatment and prevention, including the SAVI Dual Migraine Therapy device, SAVI Smart Diary for tracking treatment history and personalized patterns, and a dedicated support team for onboarding, optimizing results, monitoring progress, and managing prescription refills.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full eNeura company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Roxro Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Roxro Pharma
2.2 - Growth funds investing in similar companies to Roxro Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Roxro Pharma
4.2 - Public trading comparable groups for Roxro Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →